TECH240719C115000
- 0.70
- 0.000.00%
Bio-Techne Newsroom
Bio-Techne Corporation's (NASDAQ:TECH) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Bio-Techne (NASDAQ:TECH) has had a great run on the share market with its stock up by a significant 22% over the last three months. Given that stock prices are usually aligned with a company's
Express News | Bio-Techne Corp : Leerink Partners Cuts Target Price to $90 From $95
BIO-TECHNE TO HOST CONFERENCE CALL ON AUGUST 7, 2024, TO ANNOUNCE FOURTH QUARTER AND FISCAL 2024 FINANCIAL RESULTS
Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 a....
Welcome to the Everything Rally. How Stock Investors Can Play It.
Megacap tech stocks are no longer the only game in town. Small-caps are finding new life, and so are beaten-up sectors like real estate.
These Are the Stocks With the Highest Increase in Short Interest Within Life Sciences and Diagnostics - Baird
This Bio-Techne Insider Reduced Their Stake By 19%
Looking at Bio-Techne Corporation's (NASDAQ:TECH ) insider transactions over the last year, we can see that insiders were net sellers. That is, there were more number of shares sold by insiders than t
KeyBanc Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $80
KeyBanc analyst Paul Knight maintains $Bio-Techne(TECH.US)$ with a buy rating, and maintains the target price at $80.According to TipRanks data, the analyst has a success rate of 42.8% and a total ave
Declining Stock and Decent Financials: Is The Market Wrong About Bio-Techne Corporation (NASDAQ:TECH)?
Is There Now An Opportunity In Bio-Techne Corporation (NASDAQ:TECH)?
Today we're going to take a look at the well-established Bio-Techne Corporation (NASDAQ:TECH). The company's stock led the NASDAQGS gainers with a relatively large price hike in the past couple of
BIO-TECHNE TO PRESENT AT UPCOMING INVESTOR CONFERENCES
Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the following...
Express News | Quantum-Si Appoints Former Bio-Techne President and CEO, Chuck Kummeth, to Serve as Independent Chairman of the Board of Directors
Express News | Scaleready Announces $20 Million G-Rex® Grant Program for the Advancement of Cell and Gene Therapy (Cgt) Development and Manufacturing
Bio-Techne's (NASDAQ:TECH) Investors Will Be Pleased With Their Notable 69% Return Over the Last Five Years
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than that, you probably want to see it rise more than the market average. But Bio-Techn
BIO-TECHNE TO PRESENT AT THE 2024 LEERINK PARTNERS HEALTHCARE CROSSROADS CONFERENCE
Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the 2024 Leerink...
Citi Downgrades Bio-Techne(TECH.US) to Hold Rating, Raises Target Price to $85
Citi analyst Patrick B Donnelly downgrades $Bio-Techne(TECH.US)$ to a hold rating, and adjusts the target price from $80 to $85.According to TipRanks data, the analyst has a success rate of 48.4% and
Citi Downgrades Bio-Techne to Neutral, Cites Valuation
Demystifying Bio-Techne: Insights From 4 Analyst Reviews
4 analysts have shared their evaluations of Bio-Techne (NASDAQ:TECH) during the recent three months, expressing a mix of bullish and bearish perspectives.The following table encapsulates their recent
Bio-Techne Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/22/2024 2.81% Citigroup → $85 Downgrades Buy → Neutral 05/02/2024 14.9% Benchmark → $95 Reiterates Buy
Express News | Bio-Techne And Regulus Therapeutics Announced Continued Technical And Clinical Collaboration Following Regulus' Topline Results From The Second Cohort Of Phase 1B Multiple Ascending Study Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease
BIO-TECHNE HIGHLIGHTS RECENTLY ANNOUNCED TOP-LINE BIOMARKER DATA FROM PARTNER, REGULUS THERAPEUTICS, USING THE COMPANY'S PROPRIETARY TECHNOLOGY